TRIM9 and breast carcinoma: The evidence provided in this study was consistent with previous research conducted by Mishima et al. Through the bisulfite NGS method on breast cancer cell lines and clinical samples, the results of their study demonstrated that high TRIM9 methylation status was characteristic in over 90% of breast cancer cell lines and in over 60% of breast tumor samples.